07 Oct 2026, 15:25 IST
Laurus Labs Limited
HDFC Securities · REDUCE · target Rs 1,580
The report expects 26% YoY revenue growth and 55% YoY EBITDA growth driven by Small Molecule CDMO, naming it a strong performer despite its REDUCE rating.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.